The ATTAIN phase 3 programme (randomised, double-blind, placebo-controlled, 72 weeks) found that participants on the highest dose, combined with diet and exercise support, lost an average of 12.4% of body weight, versus around 2% on placebo.
Titration is slow - no dose increase sooner than every 30 days - so appetite changes appear in the first few weeks, measurable weight loss from around month two, and the strongest results at the maintenance dose.
Figures assume full trial adherence; individual results vary.